Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +72

Gilead Sciences completes acquisition of Arcellx ahead of commercial launch of Anito-cel

AI-generated analysis

🧬 Gilead Sciences has successfully completed its acquisition of Arcellx Inc., gaining full control of the anitocabtagene autoleucel (anito-cel) therapy.

πŸ’° The deal valued at approximately $7.8 billion includes a cash payment of $115 per share plus a $5 contingent value right.

πŸ”„ This transaction consolidates ownership of anito-cel to eliminate future profit-share and royalty obligations for the new drug.

⚑ Executives emphasized the acquisition allows Gilead to accelerate development, streamline decision-making, and maximize the therapy's long-term potential.

πŸ’Ό The tender offer resulted in Gilead holding approximately 77.2% of Arcellx's shares before finalizing the merger on April 28, 2026.

πŸ“‰ The asset acquisition is expected to reduce Gilead's diluted earnings per share by $5.57 - $5.67 in 2026 due to in-process research and development expenses.

πŸ’‘ Financial impact is expected to be modestly dilutive for the first two years post-closing but accretive starting in 2028, contingent on FDA approval.

🎯 Anito-cel is a novel BCMA-directed CAR T-cell therapy for multiple myeloma utilizing a compact D-Domain binder to reduce immunotoxicity.

βš•οΈ The drug holds Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the US FDA.

⏳ Contingent value rights are payable upon achieving cumulative global net sales of at least $6.0 billion through the end of 2029.

🏒 Following the merger, Arcellx stock has been delisted from the Nasdaq Global Select Market as it becomes a wholly owned subsidiary.

🌍 Gilead aims to combine Arcellx's science with its global manufacturing and regulatory capabilities to bring anito-cel to patients.

πŸ“… The article was published on April 30, 2026, just ahead of the commercial launch of the new anitocabtagene autoleucel therapy.

πŸ“ˆ Gilead recently announced a $32 billion investment plan in 2025 to strengthen its US footprint and expand global operations in more than 35 countries.

Bullish Signals
  • Gilead Sciences completed the acquisition of Arcellx for $115 per share plus a contingent value right of $5 per share, representing a total implied equity value of approximately $7.8 billion.
  • The transaction grants Gilead full control of anitocabtagene autoleucel (anito-cel), enabling the acceleration of development and elimination of future profit-share or milestone obligations.
  • Anito-cel has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the US FDA, signaling strong regulatory momentum for this investigational CAR T-cell therapy.
  • The novel D-Domain BCMA binder in anito-cel is designed to enable high CAR expression without tonic signaling and quickly release from the target, potentially reducing severe immunotoxicity.
  • Gilead expects the acquisition to become accretive to earnings per share starting in 2028 following US FDA approval of anito-cel, with modest dilution expected only in 2026 and 2027.
  • The contingent value right is tied to cumulative global net sales of at least $6.0 billion for anito-cel from launch through the end of 2029, highlighting strong upside potential.
Risk Factors
  • The acquisition of Arcellx is expected to reduce Gilead's GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67.
  • Gilead expects the transaction to be modestly dilutive to earnings per share in 2026 and 2027, which impacts near-term profitability.
  • The deal's accretive benefits are not realized until 2028 or thereafter, dependent on US FDA approval of anito-cel.
  • Gilead is acquiring the asset for a high price with an implied equity value of approximately $7.8 billion.
  • Contingent value rights of $5 per share are only payable upon achieving cumulative global net sales of at least $6.0 billion from launch through the end of 2029, creating significant sales targets to meet.
  • Arcellx stock will be delisted from the Nasdaq Global Select Market following the merger.
Full Analysis
Gilead Sciences Inc has completed the acquisition of Arcellx Inc for $115 per share in cash, plus one non-transferable contingent value right (CVR) of $5 per share, resulting in a total implied equity value of approximately $7.8 billion at the time of closing. The deal was finalized on April 30, 2026, following Gilead's tender offer completion on April 28, 2026, which acquired approximately 77.2% of Arcellx's outstanding shares. Through a merger with Gilead's wholly owned subsidiary, Arcellx now operates as a wholly owned subsidiary of Gilead, and its common stock has been delisted from the Nasdaq Global Select Market. This transaction grants Gilead full control over anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma, thereby eliminating future profit-share, milestone, and royalty obligations associated with the collaboration. The acquisition is structured as an asset acquisition which will impact Gilead's financial reporting, expected to reduce its GAAP and non-GAAP 2026 diluted earnings per share (EPS) by approximately $5.57 - $5.67. The company anticipates that excluding acquired in-process research and development expenses, the transaction will be modestly dilutive to EPS in 2026 and 2027, but accretive starting in 2028 and thereafter, pending US FDA approval of anito-cel. The $5 per share CVR is payable upon achievement of cumulative global net sales of anito-cel reaching at least $6.0 billion from launch through the end of 2029. Cindy Perettie, executive VP and global head of Kite, noted that the acquisition allows Gilead to execute with speed and discipline while leveraging its global manufacturing, regulatory, and commercial capabilities to advance anito-cel and its differentiated D-Domain BCMA binder within Kite. Anitocabtagene autoleucel utilizes a novel and compact D-Domain binder designed for high CAR expression without tonic signaling and quick release from the BCMA target, aiming to eliminate multiple myeloma cells effectively with reduced immunotoxicity. The therapy has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the US FDA. This acquisition consolidates Gilead's oncology portfolio, aligning with its commitment to address gaps in cancer care through next-generation therapies, including cell-based approaches. Gilead continues its broader investment strategy, having announced a planned $32 billion investment in 2025 to strengthen its US footprint and ensure patients worldwide benefit from scientific innovation across its operations in more than 35 countries.